Neuropathic pain feature in cancer-induced bone pain: does it matter? a prospective observational study
Issued Date
2023-01-01
Resource Type
ISSN
20059159
eISSN
20930569
Scopus ID
2-s2.0-85152968358
Journal Title
Korean Journal of Pain
Volume
36
Issue
2
Start Page
253
End Page
267
Rights Holder(s)
SCOPUS
Bibliographic Citation
Korean Journal of Pain Vol.36 No.2 (2023) , 253-267
Suggested Citation
Zinboonyahgoon N., Luansritisakul C. Neuropathic pain feature in cancer-induced bone pain: does it matter? a prospective observational study. Korean Journal of Pain Vol.36 No.2 (2023) , 253-267. 267. doi:10.3344/kjp.22392 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/82506
Title
Neuropathic pain feature in cancer-induced bone pain: does it matter? a prospective observational study
Author(s)
Author's Affiliation
Other Contributor(s)
Abstract
Background: Cancer-induced bone pain (CIBP) is considered to have both nociceptive and neuropathic components. However, the prevalence, risk factors, and impact of the neuropathic components are yet poorly understood. Methods: We estimate the prevalence of neuropathic pain (NP) features in patients with CIBP at a tertiary care pain clinic setting using the Douleur Neuropathique 4 questionnaire and evaluate their associated factors and their impact after 4 weeks of treatment using the Brief Pain Inventory questionnaire and the Edmonton Symptom Assessment System. Results: A total of 133 patients were recruited. The estimated prevalence of NP was 30.8% (95% confidence interval: 23.6%–39.1%). Initially, the patients with NP had significantly higher average pain scores (6.00 vs. 5.05, P = 0.006), higher total interference scores (5.84 vs. 4.89, P = 0.033), and symptom distress scores (35.88 vs. 26.52, P = 0.002). After 4 weeks of treatment, patients in both groups reported significantly decreased pain intensity and improved quality of life. However, the patients with NP still reported significantly higher average pain (4.61 vs. 3.58, P = 0.048), trending toward higher total interference scores (3.52 vs. 2.99, P = 0.426), and symptom distress scores (23.30 vs. 20.77, P = 0.524). From multivariate analysis, the independent risk factors for NP were younger age, pain in the extremities, and higher average pain scores. Conclusions: NP are common in patients with CIBP. These conditions negatively affect pain intensity and the patient’s quality of life before and after treatment.